Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The lipid bilayer of retinal photoreceptor membranes, primarily located in the outer segments of rod and cone cells, is a highly specialized biological structure essential for the initiation of vision (Giusto et al., 2000). These membranes are distinguished by an exceptionally high concentration of polyunsaturated fatty acids (PUFAs), particularly docosahexaenoic acid (DHA), which accounts for nearly 50% of the total phospholipid content (SanGiovanni & Chew, 2005). This unique lipid composition ensures the high membrane fluidity required for the rapid diffusion and conformational changes of rhodopsin and other proteins involved in the phototransduction cascade (Albert et al., 2016). Beyond structural support, the bilayer acts as a platform for the visual cycle, facilitating the regeneration of visual pigments. Due to their high PUFA content and constant exposure to light and high oxygen tension, these membranes are extremely vulnerable to oxidative damage (Bazán, 2006). The resulting lipid peroxidation leads to the formation of toxic byproducts like A2E and lipofuscin, which are implicated in the pathogenesis of age-related macular degeneration (AMD) and Stargardt disease. Therapeutic interventions targeting this bilayer often involve the use of antioxidants, such as Vitamin E and carotenoids, or the supplementation of DHA to maintain membrane integrity and function. Emerging pharmacological approaches also aim to modulate the visual cycle to reduce the metabolic stress and toxic accumulation within these lipid structures.
Antioxidant protection, modulation of membrane fluidity, and inhibition of toxic lipid byproduct accumulation
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipid bilayer of retinal photoreceptor membranes (RPM) (RPM).